GlideLink, Inc. is a platform technology company developing drug delivery system (DDS) formulations for localized injection and systemic circulation. 

Vision
Setting a New Global Standard in Formulation Platform Biotechnology

Mission
Creating partner-ready technology packages for precise and scalable global licensing-out

►Upon simple mixing of PEG and αCD, the hydrophobic repeating segments of PEG spontaneously thread into the hydrophobic inner cavity of αCD, generating strong supramolecular interactions that drive physical self-assembly. We refer to this distinctive self-assembly principle as the "Glide-in" mechanism. 

►Glide-in HydroMatrix™ (GHM) is GlideLink’s proprietary locally injectable platform for localized drug delivery. It is being developed to provide key technological advantages such as local injectability, drug-loading capability, controlled release, biodegradability, and tunable viscoelastic properties. Further technical details can be shared upon request in a confidential setting under CDA/NDA. 

►The GPP-T Series is GlideLink’s proprietary systemic circulation platform for APIs with extracellular mechanisms of action. It is being developed to provide key formulation advantages, including improved systemic exposure, pharmacokinetic optimization, and enhanced developability. Further technical details can be shared upon request in a confidential setting under CDA/NDA. 

►Tier 1. The IMD Group comprises GHM001, a prescription therapy for dry eye disease; GHM002, a depot-based glaucoma treatment; and GHM003, a therapeutic for arthritis pain relief. All three IMD assets are based on the shared GHM platform.

►Tier 2. The GPP-T Series is a systemic drug formulation platform built on next-generation PEGylation 2.0 technology for APIs with extracellular mechanisms of action.

►Both platform technologies are designed to advance rapidly through the pre-FIH stage, with a development roadmap focused on early-stage licensing-out and technology transfer.

• Head Office: #A-6, 3F, 194-25, Osongsaengmyeong 1-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea 

• Seoul R&D Office: #204, Building V1, KIST, 5 Hwarang-ro 14-gil, Seongbuk-gu, Seoul, Republic of Korea

• Business Registration No. 611-81-30865 

• Date of Incorporation: March 18, 2026 

• email: chryse@glide-in.com

• IR Biz Channel(KOR): http://pf.kakao.com/_JxdICX 

For further information on our development technologies, business activities, sector-specific partnerships, or IR materials, please contact GlideLink via email. 

[2026-0701-1] 제3자 배정 신주발행(유상증자) 공고

2026년 6월 17일 개최한 주식회사 글라이드링크의 이사회에서 상법 제418조 제2항에 따라 제3자 배정 방식의 신주발행에 관하여 아래와 같이 결의하였으므로 상법 제418조 제4항에 따라 이를 공고합니다.

1) 신주식의 종류와 수: 상환전환우선주식 2,500주

2) 신주식의 발행가액: 1주 금40,000원(액면가액 1주 금500원)

3) 신주인수대금총액: 금100,000,000원

4) 납 입 기 일: 2026.  07.  16

5) 신주식의 인수방법:

   상법 제418조 및 당 회사 정관 제9조 2항에 의거하여 기존 주주의 신주인수권을 배제하고, 전부를 제3자에게 배정한다. 

2026년 07월 01일  

주식회사 글라이드링크

대표이사 김영민, 대표이사 김장일 (직인 생략)